A Phase 2 interventional study of SP-304 0.3 mg and SP-304 1.0 mg in Chronic Idiopathic Constipation, sponsored by Bausch Health Americas, Inc.. Completed at 14 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-01-02.
Sponsored by Bausch Health Americas, Inc. (part of Bausch Health Companies Inc.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing plecanatide in Constipation — none open to participants now, 1 under way, none of them phase 3. plecanatide · Constipation.
Among the 12 studies testing plecanatide in Constipation, this one is the 12th largest by enrollment, is the only one that started in 2010, is one of 5 in phase 2, and was the 1st registered.
1,047 studies on the registry are indexed under Constipation; 161 are open to participants now.
Browse Constipation studies →None of the 12 studies testing plecanatide in Constipation is open now. The open studies under Constipation, anywhere →
plecanatide: first FDA approval 2017 (TRULANCE). What it is approved for, and how studies give it, is on its page →
Of the 99 Constipation studies recruiting now, 32 (32%) set no upper age limit and 52 (53%) stop at 75 or younger; 17 take children under 18; 28 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 6 · Phase 3 7
First in 2010; this study’s year is marked. 1 started in 2010.
This study's enrollment of 84 is above the median of 75 across 885 interventional studies indexed under Constipation.
Median enrollment 800 across the 12 interventional studies. Of the 11 that completed or were terminated, 10 (91%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 12 have an industry lead sponsor. The 2 most frequent:
This study is registered under Bausch Health Americas, Inc., one of the names counted as Bausch Health Companies Inc.. Under that name alone:
Bausch Health Americas, Inc. is the lead sponsor of 213 studies on the registry; 7 are open to participants now.
Of its 25 completed or terminated interventional studies of FDA-regulated products, 18 (72%) have results posted.
21 studies in Constipation by Bausch Health Companies Inc.: none open now, 1 under way, none of them phase 3. Of 20 finished, 15 (75%) have results posted.
Among the 21 studies in Constipation by Bausch Health Companies Inc., this one is the 17th largest by enrollment of the 20 interventional ones that give a count, is the only one that started in 2010, is one of 9 in phase 2, and was the 9th registered.
Bausch Health Companies Inc.’s Constipation studies by the year they started, since 2006.
1 of the studies testing plecanatide in Constipation that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07723924Bausch Health Americas, Inc.This is a Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study of the Efficacy and Safety of 2 Weight-based Treatment Groups of Plecanatide Versus Placebo in Children and Adolescent Participants 6 to Less Than 18 Years of Age With FC | 2027-10-18 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies testing plecanatide in Constipation, from their registry updates:
Among Bausch Health Companies Inc.’s 21 in Constipation:
This tab as a report to print or save as PDF → With an account.
This is a Phase 2a, randomized, double-blind, placebo-controlled, 14-day repeat oral, dose ranging study to determine the safety, pharmacokinetics (PK) and pharmacodynamics (PD) effects of SP-304 in patients with chronic idiopathic constipation.
This is a Phase 2a, randomized, double-blind, placebo-controlled, 14-day repeat oral, dose ranging study to determine the safety, PK and PD effects of SP-304 in patients with chronic idiopathic constipation. Patients diagnosed with chronic idiopathic constipation (CIC) will be screened for the anticipated 4 cohorts, to yield 80 randomized patients for enrollment. Four dose cohorts are planned (0.3 mg, 1.0 mg, 3.0mg, and 9.0 mg) with 20 patients per dose cohort [randomization ratio 3:1 (15 receive SP-304:5 receive placebo)]. Patients who continue to meet all the entry criteria and complete the pre-treatment bowel movement (BM) diary will receive, in a double-blind, randomized fashion, SP-304 or matching placebo. It is expected that each patient will complete all 14 days of dosing (including making accurate BM diary entries for all 14 days in the treatment period). All patients receiving at least one dose of SP-304 or matching placebo will be considered evaluable for the safety endpoints. If a patient receives at least 5 doses per treatment week (1 dose per day for 7 days) and has completed BM diary entries for those 5 dosing days in each corresponding treatment week, he/she will be considered evaluable.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
SP-304 0.3 mg tablet by mouth once daily for 14 consecutive days.
Drug: SP-304 0.3 mg
SP-304 1.0 mg tablet by mouth once daily for 14 consecutive days.
Drug: SP-304 1.0 mg
SP-304 3.0 mg tablet by mouth once daily for 14 consecutive days
Drug: SP-304 3.0 mg
SP-304 9.0 mg tablet by mouth once daily for 14 consecutive days.
Drug: SP-304 9.0 mg
Placebo tablet by mouth once daily for 14 consecutive days
Drug: Placebo
SP-304 0.3 mg
SP-304 1.0 mg
SP-304 3.0 mg
SP-304 9.0 mg
Placebo
Number of Participants With Adverse Events
Incidences of adverse events from Baseline through the end of the Follow-up period.
Time frame: 21 days: Baseline through Follow-up (Treatment Days 14, 7 days post treatment)
Change From Baseline Overall in Number of Complete Spontaneous Bowel Movements (CSBM)
Using a Daily Diary, patients recorded the number of spontaneous bowel movements having the sensation of complete evacuation (Complete Spontaneous Bowel Movement - CSBM). The total number of spontaneous bowel movements associated with a feeling of complete evacuation were summed and divided by 2 (the number of weeks in treatment). Change was calculated as the difference between the number of the CSBMs at the completion of the 2-week treatment period, versus the 14-day pretreatment baseline.
Time frame: Study days 1 through 14
Change From Baseline Overall in Number of Spontaneous Bowel Movements (SBM)
Using a Daily Diary, patients recorded the number of spontaneous bowel movements (SBM). The overall weekly frequency was calculated as the total number of SBMs divided by 2 (the number weeks of treatment). Change was calculated as the difference between the number of the SBMs at the completion of the 2-week treatment period, versus the 14-day pretreatment baseline.
Time frame: Study Days 1 through 14
Changes From Baseline Overall in Bristol Stool Form Scale (BSFS)
Using a Daily Diary, patients recorded Stool Consistency using the 7-point Bristol Stool Form Scale (BSFS) (1 = separate hard lumps, like nuts; 2 sausage shaped but lumpy; 3 = like a sausage but with cracks on surface; 4 = like a sausage or snake, smooth and soft; 5 = soft blobs with clear-cut edges; 6 = fluffy pieces with ragged edges, a mushy stool; 7 = watery, no solid pieces, entirely liquid). Changes in mean BSFS were assessed from the average 14-day pretreatment baseline to the average during the 2-week treatment period.
Time frame: Study day 1 through 14
Changes From Baseline Overall in Ease of Passage (Straining)
Using a Daily Diary, patients recorded Ease of Passage (Straining) using the 7-point Ease-of-Passage Scale (1 = manual disimpaction/enema needed, 2 = severe straining, 3 = moderate straining, 4 = mild straining, 5 = no straining, 6 = urgency, 7 = incontinent). Changes in overall ease of passage (Straining) were assessed from the average 14-day pretreatment baseline to average during the 2-week treatment period
Time frame: Study Days 1 through 14
This study was conducted between 3 March 2010 and 26 August 2010 at 14 study centers in the United States. Four dose cohorts were planned (0.3 mg, 1.0 mg, 3.0 mg, and 9.0 mg with 20 patients per dose cohort randomized in a 3:1 ratio \[15 pts receive SP-304, 5 pts receive placebo\].
| Milestone | SP-304 0.3 mg | SP-304 1.0 mg | SP-304 3.0 mg | SP-304 9.0 mg | Placebo |
|---|---|---|---|---|---|
| Started | 14 | 15 | 16 | 17 | 22 |
| Completed | 14 | 14 | 15 | 15 | 20 |
| Not completed | 0 | 1 | 1 | 2 | 2 |
| Withdrew: Withdrew consent (patient/pi) | 0 | 0 | 0 | 1 | 2 |
| Withdrew: Venipuncture failure | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Failed urine drug screen day 1 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Abnormal lab values exl 16 | 0 | 0 | 0 | 1 | 0 |
| Milestone | SP-304 0.3 mg | SP-304 1.0 mg | SP-304 3.0 mg | SP-304 9.0 mg | Placebo |
|---|---|---|---|---|---|
| Started | 14 | 14 | 15 | 15 | 20 |
| Completed | 13 | 14 | 15 | 15 | 17 |
| Not completed | 1 | 0 | 0 | 0 | 3 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Noncompliance with protocol | 1 | 0 | 0 | 0 | 0 |
| Milestone | SP-304 0.3 mg | SP-304 1.0 mg | SP-304 3.0 mg | SP-304 9.0 mg | Placebo |
|---|---|---|---|---|---|
| Started | 13 | 14 | 15 | 15 | 17 |
| Completed | 13 | 14 | 15 | 15 | 17 |
| Not completed | 0 | 0 | 0 | 0 | 0 |
Incidences of adverse events from Baseline through the end of the Follow-up period.
| Participants | SP-304 0.3 mg | SP-304 1.0 mg | SP-304 3.0 mg | SP-304 9.0 mg | Placebo |
|---|---|---|---|---|---|
| Number of Participants With Adverse Events | 3 | 6 | 2 | 6 | 4 |
Using a Daily Diary, patients recorded the number of spontaneous bowel movements having the sensation of complete evacuation (Complete Spontaneous Bowel Movement - CSBM). The total number of spontaneous bowel movements associated with a feeling of complete evacuation were summed and divided by 2 (the number of weeks in treatment). Change was calculated as the difference between the number of the CSBMs at the completion of the 2-week treatment period, versus the 14-day pretreatment baseline.
| CSBMs per week | SP-304 0.3 mg | SP-304 1.0 mg | SP-304 3.0 mg | SP-304 9.0 mg | Placebo |
|---|---|---|---|---|---|
| Change From Baseline Overall in Number of Complete Spontaneous Bowel Movements (CSBM) | 1.7 ± 2.30 | 3.3 ± 2.85 | 1.8 ± 3.75 | 2.7 ± 2.89 | 2.0 ± 3.02 |
Using a Daily Diary, patients recorded the number of spontaneous bowel movements (SBM). The overall weekly frequency was calculated as the total number of SBMs divided by 2 (the number weeks of treatment). Change was calculated as the difference between the number of the SBMs at the completion of the 2-week treatment period, versus the 14-day pretreatment baseline.
| SBMs per week | SP-304 0.3 mg | SP-304 1.0 mg | SP-304 3.0 mg | SP-304 9.0 mg | Placebo |
|---|---|---|---|---|---|
| Change From Baseline Overall in Number of Spontaneous Bowel Movements (SBM) | 2.4 ± 2.21 | 4.1 ± 4.1 | 2.4 ± 3.39 | 4.2 ± 2.88 | 2.4 ± 2.67 |
Using a Daily Diary, patients recorded Stool Consistency using the 7-point Bristol Stool Form Scale (BSFS) (1 = separate hard lumps, like nuts; 2 sausage shaped but lumpy; 3 = like a sausage but with cracks on surface; 4 = like a sausage or snake, smooth and soft; 5 = soft blobs with clear-cut edges; 6 = fluffy pieces with ragged edges, a mushy stool; 7 = watery, no solid pieces, entirely liquid). Changes in mean BSFS were assessed from the average 14-day pretreatment baseline to the average during the 2-week treatment period.
| units on a scale | SP-304 0.3 mg | SP-304 1.0 mg | SP-304 3.0 mg | SP-304 9.0 mg | Placebo |
|---|---|---|---|---|---|
| Changes From Baseline Overall in Bristol Stool Form Scale (BSFS) | 1.1 ± 1.23 | 1.8 ± 1.18 | 1.6 ± 1.53 | 1.8 ± 1.56 | 0.9 ± 1.23 |
Using a Daily Diary, patients recorded Ease of Passage (Straining) using the 7-point Ease-of-Passage Scale (1 = manual disimpaction/enema needed, 2 = severe straining, 3 = moderate straining, 4 = mild straining, 5 = no straining, 6 = urgency, 7 = incontinent). Changes in overall ease of passage (Straining) were assessed from the average 14-day pretreatment baseline to average during the 2-week treatment period
| units on a scale | SP-304 0.3 mg | SP-304 1.0 mg | SP-304 3.0 mg | SP-304 9.0 mg | Placebo |
|---|---|---|---|---|---|
| Changes From Baseline Overall in Ease of Passage (Straining) | 0.9 ± 1.05 | 1.6 ± 1.04 | 1.3 ± 1.17 | 1.2 ± 1.06 | 0.5 ± 1.12 |
Collected over 21 Days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SP-304 0.3 mg | — | 0/14 (0%) | 3/14 (21.4%) |
| SP-304 1.0 mg | — | 0/14 (0%) | 6/14 (42.9%) |
| SP-304 3.0 mg | — | 0/15 (0%) | 2/15 (13.3%) |
| SP-304 9.0 mg | — | 0/15 (0%) | 6/15 (40%) |
| Placebo | — | 1/20 (5%) | 4/20 (20%) |
| Event | SP-304 0.3 mg | SP-304 1.0 mg | SP-304 3.0 mg | SP-304 9.0 mg | Placebo |
|---|---|---|---|---|---|
| PyelonephritisRenal and urinary disorders | 0/14 | 0/14 | 0/15 | 0/15 | 1/20 |
| Event | SP-304 0.3 mg | SP-304 1.0 mg | SP-304 3.0 mg | SP-304 9.0 mg | Placebo |
|---|---|---|---|---|---|
| Elevated LipaseInvestigations | 0/14 | 2/14 | 1/15 | 1/15 | 0/20 |
| HeadacheNervous system disorders | 1/14 | 0/14 | 0/15 | 2/15 | 0/20 |
| HyperglycemiaEndocrine disorders | 0/14 | 1/14 | 0/15 | 0/15 | 0/20 |
| GastritisGastrointestinal disorders | 1/14 | 0/14 | 0/15 | 0/15 | 0/20 |
| Hiatus HerniaGastrointestinal disorders | 1/14 | 0/14 | 0/15 | 0/15 | 0/20 |
| NauseaGastrointestinal disorders | 1/14 | 0/14 | 0/15 | 0/15 | 0/20 |
| TirednessGeneral disorders | 0/14 | 1/14 | 0/15 | 0/15 | 0/20 |
| Elevated AmylaseInvestigations | 1/14 | 0/14 | 0/15 | 0/15 | 0/20 |
| Back PainMusculoskeletal and connective tissue disorders | 0/14 | 1/14 | 0/15 | 0/15 | 0/20 |
| Intermittent Right Hand PainMusculoskeletal and connective tissue disorders | 0/14 | 1/14 | 0/15 | 0/15 | 0/20 |
Safety Population: patients who received at least one dose of study medication (population for primary endpoint).
| Age, Categorical(Participants) | SP-304 1.0 mg | SP-304 3.0 mg | SP-304 9.0 mg | Placebo | SP-304 0.3 mg | Total |
|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 12 | 11 | 14 | 17 | 11 | 65 |
| >=65 years | 2 | 4 | 1 | 3 | 3 | 13 |
| Age, Continuous(years) | SP-304 1.0 mg | SP-304 3.0 mg | SP-304 9.0 mg | Placebo | SP-304 0.3 mg | Total |
|---|---|---|---|---|---|---|
| Mean | 50.5 ± 10.6 | 48.5 ± 16.17 | 47.3 ± 12.71 | 47.7 ± 14.64 | 51.1 ± 11.95 | 48.9 ± 13.24 |
| Sex: Female, Male(Participants) | SP-304 1.0 mg | SP-304 3.0 mg | SP-304 9.0 mg | Placebo | SP-304 0.3 mg | Total |
|---|---|---|---|---|---|---|
| Female | 14 | 13 | 12 | 18 | 12 | 69 |
| Male | 0 | 2 | 3 | 2 | 2 | 9 |
| Region of Enrollment(participants) | SP-304 1.0 mg | SP-304 3.0 mg | SP-304 9.0 mg | Placebo | SP-304 0.3 mg | Total |
|---|---|---|---|---|---|---|
| United States | 14 | 15 | 15 | 20 | 14 | 78 |
| Complete Spontaneous Bowel Movement Frequency(CSBMs per week) | SP-304 1.0 mg | SP-304 3.0 mg | SP-304 9.0 mg | Placebo | SP-304 0.3 mg | Total |
|---|---|---|---|---|---|---|
| Mean | 0.6 ± 0.74 | 0.5 ± 0.92 | 0.4 ± 0.54 | 0.3 ± 0.53 | 0.4 ± 0.53 | 0.4 ± 0.66 |
| Spontaneous Bowel Movement Frequency(events per week) | SP-304 1.0 mg | SP-304 3.0 mg | SP-304 9.0 mg | Placebo | SP-304 0.3 mg | Total |
|---|---|---|---|---|---|---|
| Mean | 2.2 ± 0.99 | 2.1 ± 0.93 | 1.9 ± 0.75 | 2.0 ± 1.01 | 2.2 ± 1.12 | 2.1 ± 0.95 |
| Stool Consistency (Bristol Stool Form Scale)(units on a scale) | SP-304 1.0 mg | SP-304 3.0 mg | SP-304 9.0 mg | Placebo | SP-304 0.3 mg | Total |
|---|---|---|---|---|---|---|
| Mean | 2.6 ± 0.84 | 1.8 ± 0.69 | 2.7 ± 1.56 | 2.6 ± 1.28 | 2.5 ± 0.81 | 2.4 ± 1.13 |
| Ease of Passage (Straining)(units on a scale) | SP-304 1.0 mg | SP-304 3.0 mg | SP-304 9.0 mg | Placebo | SP-304 0.3 mg | Total |
|---|---|---|---|---|---|---|
| Mean | 2.8 ± 0.79 | 2.7 ± 0.61 | 3.0 ± 0.89 | 3.0 ± 0.67 | 3.1 ± 0.64 | 2.9 ± 0.72 |
The record gives a start of Mar 2010, a primary completion of Aug 2010 and a completion of Aug 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2020, 9 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Plecanatide
Bausch Health Americas, Inc. →